Renal Cell Cancer Trials
PCYC-1128-CA
PCYC-1128-CA – A phase 1b/2 study of Ibrutinib combination therapy in selected advanced gastrointestinal and genitourinary tumors (bladder, colon, gastric, renal)
-
What type of cancer? What stage?
- Advanced GU cancer – bladder and renal
-
Who is eligible?
- Advanced GU cancer – bladder and renal
-
How will I be treated?
- Advanced GU cancer – bladder and renal
EA8143
EA8143 – A phase III randomized study comparing Perioperative Nivolumab cs observation in patients with localized renal cell carcinoma undergoing nephrectomy.
-
What type of cancer? What stage?
- Renal cell cancer
-
Who is eligible?
- Patients who are to have surgery – disease localized to kidney
-
How will I be treated?
- Nivolumab, an immunotherapy with success in lung and other cancers
CX-839-008
CX-839-008 – A phase III, randomized, placebo controlled study of Atezolizumab (Anti-PD-L1 antibody) as monotherapy and in combination with platinum chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma
-
What type of cancer? What stage?
- Renal cell cancer
-
Who is eligible?
- Patients with disease progression after first-line therapy
-
How will I be treated?
- Adds CB-839 (a drug that inhibits tumor cell nutrient uptake) to treated with Cabozantinib (a small molecule tyrosine kinase inhibitor)
For physicians: more information about this specific trial at clinicaltrials.gov.
-
Metairie, LA 70006
504.503.6289 More information -
Metairie, LA 70006
504.456.5000 More information -
Metairie, LA 70006
504.883.2968 More information
/
View All